Association of prostate cancer with vitamin D receptor haplotypes in African-Americans

Cancer Research

Volumn 58, Issue 8, 1998, Pages 1620-1623

  Ingles, Sue Ann ^a   Coetzee, Gerhard A ^a   Ross, Ronald K ^a   Henderson, Brian E ^a   Kolonel, Lawrence N ^b   Crocitto, Laura ^a   Wang, Wei ^a   Haile, Robert W ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYADENYLIC ACID; VITAMIN D RECEPTOR;

ADVANCED CANCER; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR GENE;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; COHORT STUDIES; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; GENETIC MARKERS; HAPLOTYPES; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLY A; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; UNITED STATES;

EID: 0032522635     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1997. CA Cancer J. Clin., 47: 5-27, 1997.
2. Isaaks, J. T. Prostatic cancer: an overview. Cancer Metastasis Rev., 12: 1-2, 1993.
3. Ingles, S. A., Ross, R. W., Yu, M. C., Irvine, R. A., La Pera, G., Haile, R. W., and Coetzee, G. A. Association of prostate cancer risk with vitamin D receptor and androgen receptor genetic polymorphisms. J. Natl. Cancer Inst. (Bethesda), 89: 166-170, 1997.
4. Ingles, S. A., Haile, R. W., Henderson, B. E., Kolonel, L. N., Nakaichi, G, Shi, C-Y., Yu, M. C., Ross, R., and Coetzee, G. A. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol. Biomark. Prev., 6: 93-98, 1997.
5. Reichardt, J. K. V., Makridakis, N., Henderson, B. E., Yu, M. C., Pike, M. C., and Ross, R. K. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res., 55: 3973-3975, 1995.
6. Monroe, K. R., Yu, M. C., Kolonel, L. N., Coetzee, G. A., Wilkens, L. R., Ross, R. K., and Henderson, B. E. Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat. Med., 1: 827-829, 1995.
7. Taylor, J. A., Hirvonen, A., Watson, M., Pittman, G., Mohler, J. L., and Bell, D. A. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res., 56: 4108-4110, 1996.
8. Morrison, N. A., Yeoman, R., Kelly, P. J., and Eisman, J. A. Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphisms and circulating osteocalcin. Proc. Natl. Acad. Sci. USA. 89: 6665-6669, 1992.
9. Morrison, N. Vitamin D receptor gene variants and osteoporosis: a contributor to the polygenic control of bone density. In: D. Feldman, F. H. Glorieux, and J. W. Pike (eds.), Vitamin D, pp. 713-731. San Diego: Academic Press, 1997.
10. Schwartz, G. G., Wang, M-H., Zhang, M., Singh, R. K., and Siegal, G. P. 1-α,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol. Biomark. Prev., 6: 727-732, 1997.
11. Schwartz, G. G., Lokeshwar, B. L., Selzer, M. G., Block, N. L., and Binderup, L. 1-α,25(OH)2 vitamin D and EB1089 inhibit prostate cancer metastasis in vivo. In: A. W. Norman, R. Bouillon, and M. Thomasset (eds.), Vitamin D: Chemistry, Biology, and Clinical Applications of the Steroid Hormone, pp. 489-490. Riverside, CA: University of California Printing and Reprographics, 1997.